Good afternoon, and welcome to the Fourth Quarter and Full Year 2021 Earnings Conference Call for Conformis, Inc. My name is Justin, and I will be your conference operator today. All lines have been placed on mute to prevent any background noise. After management's remarks, there will be a question-and-answer session. I would like to remind you that this call will include forward-looking statements within the meaning of the Federal Securities law, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts should be considered forward-looking. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements, including these discussed in the risk factors section of Conformis public filings with the U.S. Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements. Conformis disclaims any obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call will include time-sensitive information and is accurate only as of the live broadcast today, March 2, 2022. I will now turn the call over to Mark Augusti, President and Chief Executive Officer of Conformis. Thank you, operator, and welcome everyone to our Fourth Quarter and Full Year 2021 Earnings Call. With me today is our CFO, Bob Howe. We appreciate you joining us for an update on Conformis. Since our business update on January 6, we've continued to execute on our core growth initiatives. While early, we are receiving positive feedback on our Platinum Services Program. We continue to make strides with our Identity Imprint limited market release, and we continue to grow our hip business. From a strategy perspective, Conformis has never been positioned better. With our product lineup and new service offerings, we now have expanded revenue opportunities and a clear path to grow our margins materially over the next few years. With that being said, 2021 proved to be another challenging year for the medical community we serve. The ups and downs caused by COVID variants were further impacted by hospital staffing challenges and supply chain pressures. Through it all, Conformis stayed focused all year and achieved a number of key wins in 2021. We had a new company record for total revenue, generating $99.9 million for the year. This was driven by our exceptional performance in protecting and monetizing our IP. While we celebrate this achievement, we are not satisfied. For those who have been following our progress over the past few years, you know that product revenue is how we measure our business. Our product revenue in 2021 was roughly what it was in 2020. This was equally rewarding and frustrating. Rewarding in the sense we commenced a limited market release of both our Identity Imprint knee system and our PSI partnership with Stryker. Frustrating in that we had to do this in the face of COVID-related headwinds causing instability with elective procedures and staffing shortages at hospitals. Omicron cases have declined substantially over the past few weeks, which is a welcome trend. Although we have not yet seen a substantial change in the headwinds we are facing, we do believe clinic visits will improve throughout the year with a corresponding increase in elective procedures. Right now we do not anticipate, nor can we predict any additional variants that would have meaningful impact on our business. We still believe that as elective procedures return to a more normal level, we will see improved recovery. Although we continue to face headwinds, we are confident in our strategy. I'd like to share some highlights from those aspects which had the most activity in the past quarter. The most significant activity was devoted to the final preparation and the actual January 6 launch of our Platinum Services Program. This was a tremendous accomplishment by our entire organization. This program will allow facilities to offer a fully personalized knee system as a deluxe upgrade to their patients. At its core, we believe this program increases access and choice to a broader patient population. Medicare and commercial payers permit patients to pay out-of-pocket for non-covered deluxe services. Just as patients can pay extra for a private hospital bed or for a premium intraocular lens product, Platinum Services brings a first of its kind premium pricing structure to orthopedics, where medical facilities can charge patients an out-of-pocket fee for their upgrade, which creates a new and incremental revenue stream for the facility. While early, the program introduction has gone well. We are onboarding our current hospital and ASC facilities, and we are attracting interest from new customers across the country. The feedback remains consistent with our market research and confirms that patients are looking for a greater say in their care and are willing to pay an out-of-pocket premium to fully personalize their implant. We also had solid progress advancing our Imprint knee. Our Identity Imprint knee system combines the benefits of our personalized solutions with the convenience and flexibility of an off-the-shelf system. We believe Imprint represents a significant advancement over standard off-the-shelf knee systems since Imprint includes several of the features of our personalized knee system. We see this filling the void between the crowded off-the-shelf category and the fully personalized category where we are the only player. We recently achieved an important milestone as we successfully completed our 100th Imprint procedure. Interestingly, 45% of surgeon users are competitive, meaning those surgeons are new to Conformis. We acknowledge the need to expand our surgeon users, and we believe the product benefits of Imprint, along with the economic and efficiency benefits of our Surgery-in-a-Box model, provide a significant market share opportunity. Throughout the limited market release, the clinical feedback has been strong. During the fourth quarter and early part of the first quarter, surgeons completed a questionnaire and rated 100% of the Imprint cases as either four or five-star experience based on a number of criteria, including AP and ML, femoral and tibial bone coverage. In fact, many new surgeon users have rated the femoral fit significantly better than the competitive system they use, which is excellent news and confirms our excitement about the superior quality of the product design. We remain on track for a Q2 transition to a full market release. Lastly, our hip business had 8% revenue growth in the quarter and 19% growth for the year, which is particularly pleasing since we still have a limited product portfolio. Like knee replacements, hip procedures are very susceptible to deferral as an elective procedure. In addition, COVID has resulted in less new product trialing, which is an important requisite for growth since we are still relatively new in the hip space. We continue to focus on the training and education of the growing group of surgeons who use our hip implants. Like our knees, our hip offering leverages unique delivery model to provide customers an efficient and economic benefit solution. In addition, we made progress on our Actera primary hip stem. This will be our second stem, and we remain on track for a mid-2022 launch. Actera will be a shorter style model conducive to the popular direct anterior approach. We believe having a broader hip portfolio is important for us to attract new surgeons to Conformis. Now I'd like to shift gears and highlight two recent achievements reinforcing the compelling clinical success of our personalized knee implants. First, the Orthopaedic Data Evaluation Panel in the United Kingdom, an independent body commonly referred to as ODEP, awarded the Conformis iTotal CR knee replacement system a 7A rating, which reflects seven years of performance data as reported in the U.K.'s National Joint Registry or the NJR. The NJR is one of the most respected registries in orthopedics, so this clinical performance, as reported, is a fantastic independent validation of the quality of the Conformis personalized knee designs. The other clinical win, and perhaps even more significant, was the recent publication in JBJS Reviews, the review journal from the publishers of The Journal of Bone & Joint Surgery. This study looked at patients that had a fully personalized Conformis implant in one knee an off-the-shelf implant in the other knee. The authors reported that 72% of patients prefer their Conformis knee. Only 6% of patients prefer their off-the-shelf knee, and 22% were neutral on preference. As the authors noted, patients in this study with bilateral knee joint replacements showed an overall preference for customized total knee replacement. We believe both these studies will be of particular interest to patients considering an upgrade through our Platinum Services Program. As you know, the overall environment has been everything but predictable. We continue to believe hospitals and ASCs will return to normalized elective procedures both in the U.S. and internationally at some point in 2022. However, our planning will assume we operate in a similar environment that we've seen in the past six to eight quarters until we see a sustained improvement in our scan activity and procedure bookings. Let me now turn the call over to Bob for a more detailed financial review of the quarter. Thank you, Mark, and good afternoon, everyone. I'll start with a walkthrough of our financial highlights and then close with a few thoughts on our outlook. We reported total revenue of $15.4 million in the fourth quarter, which is down 8% from the fourth quarter of 2020 on both a reported and constant currency basis. For the year, as Mark mentioned, we hit an all-time record with $99.9 million. Product revenue was $15.3 million for the fourth quarter, which was also down 8% from the fourth quarter of 2020 on both a reported and constant currency basis. For the year, our product revenue was $58.3 million, which is roughly flat to 2020. Within product revenue, sales of our Conformis Hip System were approximately $700,000, up 8% compared to last year's fourth quarter. For the year, our hip business grew 19% in 2021 to $3 million. We expect our hip growth rates to accelerate in the second half of the year as we expand our product portfolio and trialing by surgeons resumes in earnest since it was slowed considerably during COVID. Our royalty revenue for the fourth quarter was $146,000 and a record $41.5 million for the year, which included several non-recurring but significant dollar value items relating to protecting and monetizing our IP. Our recurring licensing revenue is expected to be approximately $125,000 per quarter. Our product gross margin was 38.0% in the fourth quarter and was adversely affected by primarily two items. The first was an increase in our canceled case inventory reserve. We have seen an increase in the aging of cases that have been postponed but not yet rescheduled, as well as a lower than estimated conversion rate of these cases into revenue. The canceled case inventory reserve is associated with fully manufactured implant kits for surgeries that were postponed, and at this point, a future surgery date has yet to be scheduled. These unscheduled surgeries can still occur, and we continue to work with the healthcare facilities to get these back on the calendar. The second item is that over the past few quarters, we've experienced an increased impact from a tough labor market combined with COVID-related absenteeism. This has negatively affected our manufacturing capacity and efficiency and resulted in higher scrap, shipment delays, and a temporary increase in our delivery lead times. While there are many advantages to our just-in-time manufacturing model, it can work against us when a manufacturing facility is not operating at the right capacity and efficiency levels. To address these challenges, we've invested in recruiting new team members, focused on retaining our talented operators, and increased our focus on training to get new hires up to speed faster. For the full year, our product gross margin was 41.4%. Like many other companies, we continue to face margin headwinds from higher material, labor, and other manufacturing costs. In addition, we have felt the impact of higher cancel case inventory expense, lower sales volume, and a reduction in selling price. Until the medical facility environment normalizes and we are operating closer to our target capacity and efficiency levels, we expect our gross margin rates to remain in the high 30s%-low 40s%. However, as the environment improves, we should be able to ramp our gross margins back to the mid-40s%. Longer term, we expect our gross margin to increase meaningfully, driven by growth of our Imprint products, which is targeted to have gross margins in the low 70s% at scale, and our Platinum Services, which is targeted in the low 60s% at scale. Total operating expenses for the fourth quarter were $19.3 million, which reflects the investment we are making in sales and marketing and R&D. It also reflects the planned higher G&A related to the investment in professional fees to protect our IP. G&A was also impacted by higher freight expense as we relied more heavily on expedited shipping methods as a result of our manufacturing capacity challenges. In 2021, we finished the year with $68.7 million of total operating expenses. This includes the planned investments we made in the second half of the year and was in line with our previous guidance. We continue to closely manage our expense structure and have focused the majority of our investments towards supporting our growth plan. For 2022, we expect operating expenses to be between $75 million and $81 million, which reflects continuation of our planned investment to drive our growth, as well as associated variable expense increases as a result of this growth. I'll walk through how 2022 compares to 2021 and highlight a few key areas driving the year-over-year increases. From a high level, like almost all companies, we're facing a tough labor market. Turnover is higher than normal, and finding qualified talent is taking much longer and is more expensive. We have addressed this by adjusting compensation for our workforce to align with current market trends. This impacts all operating expense categories to an extent. For sales and marketing, we had $24.9 million in 2021. We anticipate sales and marketing expenses to be between $29 million and $32 million in fiscal year 2022. At the high end of this range, about half of the increase is related to variable costs associated with the revenue growth, and half is related to the continuation of planned investments that we started in the second half of 2021 to support Imprint and other product introductions and the launch of Platinum Services Program. For R&D, we had $14.8 million in 2021. For 2022, we expect R&D to be between $16 million and $17 million. This increase is to continue to drive our priority products in our development pipeline, add AI technology to enhance our CAD process, and support our regulatory efforts to transition to European Union Medical Device Regulation. Finally, for G&A, we had $29.0 million in 2021. For 2022, we expect G&A to be between $30 million and $32 million. The increase is primarily driven by higher compensation expense, increased rate costs, and additional investments to support IT initiatives. Moving to our bottom line performance, we generated a net loss of $16.0 million in the quarter, or $0.09 per share. This included foreign currency exchange loss of $865,000 compared to foreign currency exchange income of $1.7 million in the same period last year. Interest expense was $1.7 million compared to $0.6 million in the same period last year. This increase was due to $1.1 million of expense related to the extinguishment of debt recognized as a result of our debt refinancing. Our balance sheet remained strong as we had cash and cash equivalents of $100.6 million at the end of the fourth quarter. This included the $15.5 million of license and royalty payments I mentioned last quarter that we received in October. One balance sheet item to note is inventory. We expect to continue to build our inventory of Imprint knees as well as Actera hip over the coming quarters to support our product launch cadence. As noted earlier, we refinanced our credit facility in November. This new $21 million facility extends the term until 2026, has a three-year interest-only period, a reduced interest rate, and includes more favorable covenants. Lastly, I would like to provide some thoughts on our outlook. Based on our performance through February and our forecast for March, we expect Q1 product revenue to be between $13.5 million-$14.5 million. This compares to the first quarter of 2021, which was $13.7 million. Our Q1 guidance reflects the forecasted impact from continued disruption of elective procedures caused by Omicron variant, staffing shortages in the medical facilities, and our own manufacturing capacity challenges. With that, Mark and I are happy to take your questions. Thank you. As a reminder, to ask a question, you'll need to press star one on your telephone. To withdraw your question, press the pound key. Please stand by while we compile the Q&A roster. Our first question comes from Kyle Rose from Canaccord Genuity. Your line is now open. Great. Thank you for taking the questions. Just wondered if we could kinda, you know, walk through your expectations maybe beyond the Q1, just with respect to all the moving pieces you have on the revenue line this year. When we think about, you know, Stryker, and that relationship rolling out, as well as, you know, the combination of the full launch from, the Platinum Services as well as Imprint, can you kind of help us understand the puts and takes of what you're thinking for the full year number? Hey, Kyle, it's Mark. I'll let Bob have a chance to comment. I think what we're looking at is sequential quarter-to-quarter improvement of the top line. That'll be through continued launch of our Imprint and our Platinum Services Program. I think in the back half, it's benefited a little more from the launch of the hip stem, so hip will sort of continue to contribute to that growth a little more in the back half. Stryker's in there, again, as I said before, we're not really gonna comment too meaningfully on that out of respect for the relationship. You know, it's showing just lower than maybe I personally would like, but continued growth. Lower actual sales, but continued sales each month. I mean, like us with our, you know, launches and stuff, you know, the industry, which, you know, Stryker's a part of, is impacted by, you know, the Omicron and the stuff in January and, you know, the economy being closed. For instance, you know, I know personally, we couldn't have a sales meeting. I think other companies got affected by that. The ability to train sales force, launch new products have been impacted. A lot of those plans for 2022 that companies like to launch in Q1 have sort of been pushed out later in the year. I think we'll, you know, continue to see some continued growth from that. But thematically, what we're looking for is, you know, sequential quarter-to-quarter growth improvement throughout 2022. Right. Okay? Yeah. The only thing I would add, I think, is obviously there's an assumption we had signaled, you know, a range of $60-$70 on our January 6th call. You know, the $60 represents if the market doesn't really improve. That's kind of the downside case scenario. $70 obviously assumes it improves, so obviously sequential improvement would be benefited by an improvement in the overall elective procedure market. Yeah, absolutely. Okay? Yeah. Then just one more on my end is could you just talk about, maybe break down the gross margin headwinds that you saw in Q4? I mean, how much of that is royalty reserve versus how much of that is coming from just the input costs and capacity constraints? Just really trying to understand, you know, those two pieces and with respect to how gross margins are gonna shake out for the full year. I'll let Bob, again, you know, touch on more detail. There's no doubt, as you know, he said in the prepared remarks, there was some one-off true-up stuff. I mean, canceled cases, as you might imagine, in this environment are higher than we've typically run. We decided to go ahead and, you know, make that provision in Q4. We're gonna keep looking at that, you know, obviously throughout 2022. There's no doubt that, you know, labor input, as Bob Howe, has gotten higher. You know, with turnover, it's a challenge on that. You know, that's impacted us. Some small things from raw materials, I don't think it's been crazy, but we're seeing, you know, we're seeing some of that continue to come through. That's a challenge for all medical med tech companies, and so we're bearing some of that as well. I can tell you first quarter in 2022, right, we're not, you know, I don't think I'll let Bob talk about it, but there's no doubt that January was a tough month. We're seeing some sequential improvement through February. We're hoping that March holds up. January was a tough month, and it was a tough month all around, you know, not only on the revenue line, but as you might imagine that then impacted efficiencies. Because, you know, we had a ton of absenteeism late December and all through January due to our manufacturing sales force workforce is up here in the New England area primarily, and we got really hit hard with Omicron. The good news is people got through it healthy, they were able to come back, you know, I'm pleased to say on that. When you see the kind of absenteeism we experienced, it's hard to run an efficient plant. That was a challenge for us, but we should see some sequential improvement in gross margin as well, not only through top line improvement, but also through efficiency improvement. With that, I'll, you know, Bob. Yeah. I mean, just specifically on the question on Q4, you know, and bridging it, I mean, I would say the canceled case, you know, adjustment, was probably about a third of the headwind. I mean, without that, we probably would've been in the low 40s, which is roughly where we were thinking. Outside of that, you know, you probably have a third that's due to efficiencies. A little tricky to get an exact number on that, as you can imagine. You know, there's probably another 20-30% that's, you know, inputs, whether it's labor or whether it's raw materials. That's probably directionally, Kyle, in the vicinity. There's a little bit of price, but that's not the biggest driver. Okay. Thank you. Thanks, Kyle. Thank you. Our next question comes from Steven Lichtman from Oppenheimer. Your line is now open. Thank you. Hi, guys. I wanted to start off with Imprint. Great data point on the competitive surge in conversion, that 45%. I was wondering also what you're seeing in terms of the location of these procedures. Are most of them now ASC? And what is your thought in terms of where the mix of ASC versus hospital will be for Imprint as you look out over the next couple of years? Okay. Steve, you know, I will tell you, I don't wanna put a number on it because I don't wanna be wrong, and we are looking at that, and we're looking at potentially providing more color on that for you guys as we go through the year. I mean, it's a little early. I will say it's primarily ASC. It's a lot of ASC. I'm not gonna say there's not any in the hospital because there's some. Without giving you an exact number, it's a lot of ASC. It's a great question I wanna get to, but that's one of the reasons why we're in a challenging time, and there's a lot of things buffeting us, but we're really excited about our strategy because we're having a lot of productive conversations with Imprint to, you know, for, you know, ASC utilization, which is, you know, what we targeted. We're really pleased about how that, you know, is sinking in. Great. On Platinum Services, based on what you're seeing so far, do you anticipate the whole custom program to be converted to Platinum by September? I think that's when you had targeted before. Yeah, that's still our plan. I'm not sure it'd be the whole custom program, but I think what you mean, which is right, is the only way to access a fully personalized knee will be through the Platinum Services Program starting in September. Now, to be clear, that between now and then, it's really only our existing users that we're transitioning. Starting, you know, as we speak, you know, new customers, which we're getting with Imprint, new customers only can get to the fully custom product through Platinum Services. But yes, by September, that'll be the only way to get a fully custom implant from Conformis. Great. Last question, and then, yeah, that's what I had meant. Thanks, Mark. Then on the new primary hip stem in mid-2022, should I assume that would be a limited launch in the back half and that the sort of the full benefit of the portfolio on hip we should really be targeting for 2023, or will that be a more of a full launch in the back half? Yeah. Yeah, that's pretty much our cadence. Knock on wood, hopefully the limited release will go well, and we'll only be in limited release for a couple quarters, and then we will get close to a full year benefit. That would be the plan in 2023. Yeah, that's the way to think about it. You know, as you know, our numbers are smaller with our hip franchises. Even in limited release, it, again, you don't know until you're there, but it should be able to incrementally drive growth for us because we've got a small base we're working off of even in limited release. Okay. Got it. Thanks, Mark. Thank you. Our next question comes from Josh Jennings from Cowen. Your line is now open. Hi. Good afternoon. Thanks for taking the questions. I was hoping to just make sure I was clear on the full year guidance and just that you are formally reiterating that $60 million-$70 million today. Sorry, I just didn't see the press release or in the formal remarks, but I think you answered in one of the questions that that is still in play. Yeah. I mean, I think the way I would say it is the answer is yes, and if we saw a need to say something different, we would tell you. You know, it's our expectations for the full year haven't changed. Great. No, thanks for that. I just wanted to make sure we were clear on that. Second, just thinking about the hikes in labor costs, is that pertinent to the sales force? If so, is this an opportunity where you can spend a little bit more to pluck off some talent? Or on the other hand, are you seeing any pressure for reps leaving for greener pastures, if you will? Is there just an overall kinda sales rep hopscotch going on in Q1 across the industry? Well, that's a really interesting question, Josh. I haven't thought of it that way. When we refer to this and what we're experiencing is really our employee workforce, our W-2 workforce. As you know, most, not all, but most of our sales reps are commissioned agents. We're not seeing losses there through that or anything around that. As a matter of fact, I will tell you, and it's one of the statistics we'll look at, but we, you know, led by our commercial team, we are making changes in our agent structure. Our leadership team. They're doing a great job. We're seeing a lot of interest from new agents coming to Conformis because the Imprint and Platinum Services story is attracting them. I think we're gonna, you know, plan to be adding significantly to our sales force, and I'll probably talk through some of those metrics as we have something to report in Q1 at our Q1 earnings call. That's our goal, I can say publicly. Like, it's always been our goal, but it's been hard during COVID, you know, to do that. 2020 was basically a lost year, and 2021 was a little challenging, and we hadn't really gotten into the launch of Imprint. Now that it's out there, people are seeing that it's real. We're delivering on it. They're seeing the story. They understand the ASC strategy, and that's gaining traction. That's the best word I can say, is it's gaining traction. Good agents in orthopedics, if nothing else, they're good at sniffing out an opportunity to make money, and that gets through, you know, a good story to sell and a good product to represent. That's what we have with Imprint and Platinum Services. Great. Just one last follow-up. Just in terms of the, your expectations for recovery in the U.S. versus Europe, any difference there in terms of the pacing and the cadence or what you're seeing so far in Q1? Thanks a lot. Yeah. I'll let Bob talk about that. I think he's a little closer. In general, Europe is still a challenge for us as a company because number one, we're even more limited in our critical mass and support. The challenge we have is still if you think about our we don't have any plans to launch Hip at this point internationally. Our knee portfolio is challenged as always through reimbursement challenges and pricing and other stuff. The MDR regulation has continued to be a big headwind that we have to get through and represent a risk. Where we wanna go is we'd like to get to Imprint as the main product over there. Except for limited opportunities in certain markets, we don't see the same opportunity that we have in the U.S. with Platinum Services. While we're thinking about adding distribution in Japan and then Australia is gone and some other areas, there's just still risk for us as we think about that. The recovery, frankly, isn't. I don't believe it's gonna be as pronounced as much because our biggest revenue source is still Germany, and Germany still is just a reimbursement drag on us because all we have is the fully personalized revenue, and that's what they're banging on. It's a challenge for us. Having said that, it's become almost to the point, Josh, where it's still meaningful, but it's barely more than 10% of our revenue at this point where, you know, it was higher, right? Well, actually, we're right about 10%. Right about there, yeah. Right. You know, give or take a few points. It continues to be challenging for us, but we continue to push at some of the new countries that we wanna launch. Yeah. I mean, Mark hit on, you know, all the points. I mean, we don't have the growth drivers overseas that we do in the U.S., but, you know, we do have some arrangements like with Australia, for instance, which we are hopeful and we wanna see it, but. We're seeing there. Right. We're starting to see it. I would say for next year, you know, take a little more conservative. Hopefully, procedures will benefit like they have in the U.S. with a recovery in like the procedure market. Clearly, they don't have the growth drivers that we have. I think, I mean, we don't report out. I don't believe every country by country, but the issue is even though we get certain growths in some of the smaller countries, and that's helpful. Germany has been such a big portion of the international revenue line, the OUS revenue line, that as Germany struggles, it's just. It's, you know, as you know, Josh, because you follow the company. I mean, I've been very transparent about it. It's a continued challenge for us and, you know, struggling through COVID even hurt more. Understood. Thanks, gentlemen. Thank you, Josh. Appreciate it. Operator, any more questions? I'm showing no further questions. I would now like to turn the call back over to Mark Augusti for closing remarks. Thank you, operator. Once again, thank you everyone for participating today. We have a solid strategy, and we're focused on executing it. We continue to believe our move to Platinum Services Program and the Imprint system focused on the ASCs is the right thing to do, and it really reinforces our unique and differentiated portfolio. Most importantly, it's allowing us to implement a disruptive pricing model to arthroplasty. That's like a key insight that I focus on and we're excited about. On behalf of our leadership team, I wanna thank our entire employee base for doing their part to help our surgeons do business easier and help our patients continue to gain pain-free lives. I mean, it has been tough at the close of the year and in January, but all of our employees are making a difference with our surgeon patients and patients. We're gonna be participating in several healthcare investor conferences over the coming months, so we look forward to seeing our community there and talking more about the company. Thank you for your interest, and have a great evening. Thank you. This concludes today's conference call. Thank you for participating. You may now disconnect.